Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus

CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved for the treatment of breast cancer in combination with endocrine therapy cause G1 cell cycle arrest, whereas adenoviruses ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Jana, Schober, Sebastian J., Hindupur, Sruthi V., Schöning, Caroline, Klein, Florian G., Mantwill, Klaus, Ehrenfeld, Maximilian, Schillinger, Ulrike, Hohnecker, Timmy, Qi, Pan, Steiger, Katja, Aichler, Michaela, Gschwend, Jürgen E., Nawroth, Roman, Holm, Per Sonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365808/
https://www.ncbi.nlm.nih.gov/pubmed/35948546
http://dx.doi.org/10.1038/s41467-022-32087-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365808/
https://www.ncbi.nlm.nih.gov/pubmed/35948546
http://dx.doi.org/10.1038/s41467-022-32087-5

Ejemplares similares